ROCKVILLE, Md., Nov. 2, 2004 (PRIMEZONE) -- Cytomedix, Inc. (OTCBB:CYME) today announced an expansion of the company's patent litigation legal representation with the engagement of Fish & Richardson on a contingent fee basis. In addition to this Boston-based firm, the company is also represented by intellectual property attorneys from two highly respected Chicago-based firms, Fitch, Even, Tabin & Flannery and Robert F. Coleman & Associates and Little Rock-based Williams & Anderson PLC.
"An important component of the company's strategy is to aggressively pursue healthcare companies and medical device providers that infringe the company's patents relating to the treatment of wounds and other damaged tissue using materials released by platelets during the platelet release reaction. The engagement of Fish & Richardson to pursue infringement claims under the Knighton Patent on a contingency basis further strengthens our ability to pursue multiple legal actions and settlements simultaneously. It also underscores the strong belief these outstanding law firms share with us in the legitimacy of our claims," stated Dr. Kshitij Mohan, chief executive officer of Cytomedix.
"We are excited about the opportunity to defend the Cytomedix technology, which has the potential to cure virtually incurable wounds, save limbs and provide enormous benefits in surgery and to society. We have been impressed by the focus, commitment and energy of Cytomedix's management and staff, and appreciate having an important role in helping to effectuate the intent of the United States patent system to reward such innovation and creative energy in the field of medicine," said Frank Porcelli, lead trial counsel for the Fish & Richardson Cytomedix team and a principal of the law firm with more than thirty years of experience as a patent trial lawyer.
About Fish & Richardson
Founded in 1878, Fish & Richardson P.C. is a national litigation and technology law firm with a highly respected reputation in the area of intellectual property. The firm, with offices in Boston, Dallas, Delaware, New York, San Diego, Silicon Valley, Twin Cities, and Washington, D.C., has prosecuted and litigated many of the fundamental patents of an industrialized America, serving corporations that created many cutting-edge technologies of the day: the telephone, the air-brake, the steam turbine, the automobile, and the radio, and, more recently, the fiberglass orthopedic cast and Post-it(r) notes. Fish and Richardson's clients have included Thomas Edison, Alexander Graham Bell and the Wright Brothers, and more recently, the 3M Company, the Gillette Company, Intel and Microsoft. Additional information is available at the firm's website at www.fr.com.
About Cytomedix
Cytomedix, Inc. is a biotechnology company specializing in processes and products derived from autologous platelet releasates. The company owns proprietary technology for the creation of autologous platelet gel composed of multiple growth factors and fibrin matrix. Additional information is available at the company's website at www.cytomedix.com.
Forward-Looking Statements
Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall with the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix's actual results may differ materially due to a number of factors, many of which are beyond Cytomedix's ability to predict or control, including among others, governmental regulation, acceptance by the medical community and competition. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc.